title: Progress in pancreatic cancer: moving beyond gemcitabine?
authors.forename: Bristi
authors.initials: B
authors.lastname: Basu
authors.forename: Duncan
authors.initials: D
authors.lastname: Jodrell
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D033721:Equilibrative Nucleoside Transporter 1 / Q000378:metabolism; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality / Q000601:surgery; D000093542:Gemcitabine
chemical_list: D033721:Equilibrative Nucleoside Transporter 1; D009944:Organoplatinum Compounds; C438649:SLC29A1 protein, human; D000077150:Oxaliplatin; D003841:Deoxycytidine; D000077146:Irinotecan; D002955:Leucovorin; D002166:Camptothecin; D000093542:Gemcitabine